Infectious complications after tocilizumab in patients with COVID: a real-world experience

Authors

Hongli Liu, Internal Medicine, Rochester General HospitalFollow
Chengu Niu, Internal Medicine, Rochester General Hospital
Ahmed Elkhapery, Internal Medicine, Rochester General Hospital
Kaiwen Zhu, Internal Medicine, Rochester General Hospital
Lakshmi G Nair, Internal Medicine, Rochester General Hospital
Zauraiz Anjum, Internal Medicine, Rochester General Hospital
Charoo Iyer, Internal Medicine, Rochester General Hospital
Hafsa Faisal, Internal Medicine, Rochester General Hospital
Ming Chow, Pulmonary and Critical Care, Rochester General Hospital

Abstract

Introduction Controversies remain regarding the safety of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this study, we seek to describe the infectious complications after tocilizumab in COVID patients and determine the related risk factors. Methods A single-center retrospective observational study was conducted among adult patients with SARS -CoV-2 infection admitted between 06/01/2020 and 12/31/2021 who received tocilizumab at our institution. Baseline demographics and laboratory values are obtained through reviewing electronic medical records. Risk factors of infectious complications after tocilizumab are identified through regression analysis. Statistics are performed using SPSS. P-value

Recommended Citation

Liu, Hongli; Niu, Chengu; Elkhapery, Ahmed; Zhu, Kaiwen; Nair, Lakshmi G; Anjum, Zauraiz; Iyer, Charoo; Faisal, Hafsa; and Chow, Ming (2023) "Infectious complications after tocilizumab in patients with COVID: a real-world experience," Journal of Community Hospital Internal Medicine Perspectives: Vol. 13: Iss. 1, Article 3.
DOI: 10.55729/2000-9666.1141
Available at: https://scholarlycommons.gbmc.org/jchimp/vol13/iss1/3